Observational studyTranslational psychiatry2019
Brain-derived neurotrophic factor as a possible predictor of electroconvulsive therapy outcome.
Observational study in Translational psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Brain-Derived Neurotrophic Factor (BDNF) as a Predictor of Treatment Response in Major Depressive Disorder (MDD): A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Baseline Plasma BDNF Levelsare Associated with Antianhedonic Effects of Repeated-Dose Intravenous Ketamine in Major Depressive Disorder.Current neuropharmacology · 2023Trial
- Trial
- Transcranial Stimulation Methods in the Treatment of MDD Patients-The Role of the Neurotrophin System.International journal of molecular sciences · 2025Review
- Is Cerebrolysin Useful in Psychiatry Disorders?Biomedicines · 2025Article
- Neurobiological Mechanisms of Electroconvulsive Therapy: Molecular Perspectives of Brain Stimulation.International journal of molecular sciences · 2025Review
- Hamayou () protein hydrolysate ameliorates depression by regulating the mitogen-activated protein kinase pathway.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- Electroconvulsive therapy in the Fourth Industrial Revolution (Review).Biomedical reports · 2024Review
- The role of neurotrophic factors in novel, rapid psychiatric treatments.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- Alterations in the Serum Proteome Following Electroconvulsive Therapy for a Major Depressive Episode: A Longitudinal Multicenter Study.Biological psychiatry global open science · 2023Article
- Antidepressant pharmacological mechanisms: focusing on the regulation of autophagy.Frontiers in pharmacology · 2023Review
- Adult hippocampal neurogenesis: pharmacological mechanisms of antidepressant active ingredients in traditional Chinese medicine.Frontiers in pharmacology · 2023Review
- Electroconvulsive Therapy in Psychiatric Disorders: A Narrative Review Exploring Neuroendocrine-Immune Therapeutic Mechanisms and Clinical Implications.International journal of molecular sciences · 2022Review
- Biomolecular Research on Electroconvulsive Therapy for Mental Disorders: State of the Art and Future Directions.Alpha psychiatry · 2022Article
- Antidepressant Active Components of Bupleurum chinense DC-Paeonia lactiflora Pall Herb Pair: Pharmacological Mechanisms.BioMed research international · 2022Review
- The ratio and interaction between neurotrophin and immune signaling during electroconvulsive therapy in late-life depression.Brain, behavior, & immunity - health · 2021Article
- Methylome-wide change associated with response to electroconvulsive therapy in depressed patients.Translational psychiatry · 2021Article
- Diabetes mellitus type 2 impedes functional recovery, neuroplasticity and quality of life after stroke.Journal of family medicine and primary care · 2020Article
- BDNF and the Antidepressant Effects of Ketamine and Propofol in Electroconvulsive Therapy: A Preliminary Study.Neuropsychiatric disease and treatment · 2020Article
- The Diagnostic Value of the Combination of Serum Brain-Derived Neurotrophic Factor and Insulin-Like Growth Factor-1 for Major Depressive Disorder Diagnosis and Treatment Efficacy.Frontiers in psychiatry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While brain-derived neurotrophic factor (BDNF) has been shown to predict response to pharmacotherapy in depression, studies in electroconvulsive therapy (ECT) are small and report conflicting results. This study assesses the association between pre-treatment BDNF levels and ECT outcome in severe late-life unipolar depression (LLD). The potential of BDNF as a clinical predictor of ECT outcome was subsequently evaluated. Characteristics associated with low and high BDNF subgroups were determined as well. Ninety-four patients diagnosed with LDD referred for ECT were included. Fasting serum BDNF levels were determined before ECT. Remission and response, measured with the Montgomery-Åsberg Depression Rating Scale, were the outcomes. The association between BDNF and ECT outcome was analysed with logistic regression and Cox regression. The clinical usefulness of BDNF was evaluated using the receiver operating characteristic (ROC) curve. Associations between clinical characteristics and low versus high BDNF levels were examined with T tests, chi-squared tests and Mann-Whitney tests. The odds of remission decreased with 33% for every five units increase of BDNF levels (OR 0.67, 95% confidence interval 0.47-0.96; p = 0.03); however, neither the association with time to remission nor the associations with response nor the adjusted models were significant. The area under the ROC (0.66) implied a poor accuracy of BDNF as a clinical test. Clinical characteristics associated with BDNF were inclusion site, physical comorbidities and duration of the index episode. To conclude, although there is an association between pre-treatment BDNF levels and ECT outcome, BDNF cannot be considered an eligible biomarker for ECT outcome in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.